Further studies are required to determine if fracture risk is decreased with anti-RANKL treatment alone or with bisphosphonates following anti-RANKL discontinuation in DMD and other states of GC-induced osteoporosis. This evidence concerns the gene TNFSF11 and osteoporosis.